Drugmakers To Pay For Hospital Overspend?

BMI View: We maintain our forecast of deteriorating prospects for drugmakers in Italy, as in addition to a decline in public spending on pharmaceuticals (enforced by price cuts on medicines), company revenue streams will remain under pressure as hospitals are delaying payments worth billions of dollars. Our bearish outlook takes into account the deteriorating state of the economy and the country's enormous public debt

To read the full article, please choose one of the following options: